AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16381354 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled laparoscopic hernia repair
Number of subjects: 49
Study 16381354 — intervention group
Group type: COMPARATOR
Intervention: Unstapled laparoscopic hernia repair
Number of subjects: 49
Study 11908539 — intervention group
Group type: EXPERIMENTAL
Intervention: High participation units (n = 18)
Number of subjects: 235
Study 11908539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low participation units (n = 10)
Number of subjects: 235
Study 11908539 — intervention group
Group type: COMPARATOR
Intervention: Control units (no formalized research groups or activities)
Number of subjects: 235
Study 11908539 — intervention group
Group type: EXPERIMENTAL
Intervention: All units (high, low, and control)
Number of subjects: 235
Study 10442371 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (300 mg/day) plus oral calcium folinate (90 mg/day) and vinorelbine (15 mg/m2)
Number of subjects: 0
Study 7531223 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP16B (cisplatin 20 mg/m2 on days 1 to 5 + etoposide 100 mg/m2 on days 1 to 5 + bleomycin 30 IU/wk for 9 consecutive weeks)
Number of subjects: 178
Study 7531223 — intervention group
Group type: COMPARATOR
Intervention: PVP16 (cisplatin 20 mg/m2 on days 1 to 5 + etoposide 100 mg/m2 on days 1 to 5)
Number of subjects: 178
Study 7531223 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP16B
Number of subjects: 178
Study 7531223 — intervention group
Group type: COMPARATOR
Intervention: PVP16
Number of subjects: 178
Study 2193271 — intervention group
Group type: EXPERIMENTAL
Intervention: estrone sulfate 0.625 mg
Number of subjects: 153
Study 2193271 — intervention group
Group type: EXPERIMENTAL
Intervention: estrone sulfate 1.25 mg
Number of subjects: 153
Study 2193271 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 153
Study 387204 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 FU infusion with mitomycin-C
Number of subjects: 0
Study 387204 — intervention group
Group type: COMPARATOR
Intervention: 5 FU infusion with methyl-CCNU
Number of subjects: 0
Study 31389859 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A1 (80 kVp, 40 mL CM, iterative reconstruction)
Number of subjects: 60
Study 31389859 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A2 (80 kVp, 40 mL CM, AI-based noise reduction)
Number of subjects: 60
Study 31389859 — intervention group
Group type: COMPARATOR
Intervention: Group B (120 kVp, 80 mL CM, iterative reconstruction)
Number of subjects: 60
Study 31389859 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (combined A1 and A2)
Number of subjects: 60
Study 29995458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g/day) for 6 days
Number of subjects: 14
Study 29995458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 26914909 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 3924
Study 26914909 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine-Tenofovir Disoproxil Fumarate (FTC-TDF)
Number of subjects: 3924
Study 26914909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3924
Study 25185586 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised physical activity on prescription
Number of subjects: 49
Study 25185586 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 22378483 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline demographic and clinical variables
Number of subjects: 539
Study 20705231 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE intervention (n=153)
Number of subjects: 292
Study 20705231 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (n=139)
Number of subjects: 292
Study 17541110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 0
Study 17541110 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 0
Study 16388724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine (250 mg/day) for 6 weeks
Number of subjects: 174
Study 16388724 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 174
Study 17293471 — intervention group
Group type: EXPERIMENTAL
Intervention: BTB autograft
Number of subjects: 71
Study 17293471 — intervention group
Group type: COMPARATOR
Intervention: ST autograft
Number of subjects: 71
Study 17293471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BTB and ST autografts
Number of subjects: 71
Study 11081335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 9
Study 8783533 — intervention group
Group type: EXPERIMENTAL
Intervention: FluroShield
Number of subjects: 86
Study 8783533 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 86
Study 1537129 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase plus heparin
Number of subjects: 334
Study 1537129 — intervention group
Group type: COMPARATOR
Intervention: Alteplase plus placebo
Number of subjects: 334
Study 1537129 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin with adequate anticoagulation
Number of subjects: 334
Study 1537129 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin with patent vessels
Number of subjects: 334
Study 1537129 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin with recurrent ischemia
Number of subjects: 334
Study 1537129 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin with left ventricular thrombosis
Number of subjects: 334
Study 6733194 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined lifting a 16 gram or 35 gram weight
Number of subjects: 0
Study 6733194 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual lifting of a 16 gram or 35 gram weight
Number of subjects: 0
Study 6733194 — intervention group
Group type: EXPERIMENTAL
Intervention: Adopting an agreeable attitudinal set while reading neutral text
Number of subjects: 0
Study 6733194 — intervention group
Group type: EXPERIMENTAL
Intervention: Adopting a disagreeable attitudinal set while reading neutral text
Number of subjects: 0
Study 6733194 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining reading an editorial
Number of subjects: 0
Study 6733194 — intervention group
Group type: EXPERIMENTAL
Intervention: Silently reading neutral text
Number of subjects: 0
Study 30980133 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed run sprint interval training (INT)
Number of subjects: 29
Study 30980133 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 29
Study 30980133 — intervention group
Group type: COMPARATOR
Intervention: Both INT and MICT
Number of subjects: 29
Study 28752580 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 55
Study 28752580 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 55
Study 27460620 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Coping-Oriented Therapy (COP)
Number of subjects: 196
Study 27460620 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (SUP)
Number of subjects: 196
Study 24636483 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 44
Study 24636483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23342561 — intervention group
Group type: EXPERIMENTAL
Intervention: Precaine (8% Lidocaine + 0.8% Dibucaine)
Number of subjects: 60
Study 23342561 — intervention group
Group type: EXPERIMENTAL
Intervention: Precaine B (20% Benzocaine)
Number of subjects: 60
Study 20393432 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine, a dopaminergic drug, dosage and duration not specified
Number of subjects: 0
Study 18690809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL
Number of subjects: 65
Study 18690809 — intervention group
Group type: COMPARATOR
Intervention: Nephrostomy drainage
Number of subjects: 65
Study 15714982 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel as a single agent
Number of subjects: 0
Study 15714982 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel combined with estramustine or other antimicrotubular agents
Number of subjects: 0
Study 15714982 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with prednisone
Number of subjects: 0
Study 12846341 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 25
Study 12846341 — intervention group
Group type: COMPARATOR
Intervention: Trovafloxacin
Number of subjects: 25
Study 10377207 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone metered dose inhaler (pMDI) 250 microg, 8 puffs
Number of subjects: 16
Study 10377207 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone pMDI 250 microg, 8 puffs + mouth rinsing/gargling (water)
Number of subjects: 16
Study 10377207 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone pMDI 250 microg, 8 puffs + mouth rinsing/gargling (charcoal)
Number of subjects: 16
Study 10377207 — intervention group
Group type: COMPARATOR
Intervention: placebo pMDI, 8 puffs + mouth rinsing/gargling (water)
Number of subjects: 16
Study 8710072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine > 80 mg/d
Number of subjects: 663
Study 8710072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine > 120 mg/d
Number of subjects: 663
Study 2029947 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based clinics providing reproductive health services
Number of subjects: 0
Study 2029947 — intervention group
Group type: COMPARATOR
Intervention: School-based clinics providing contraceptives on site
Number of subjects: 0
Study 2029947 — intervention group
Group type: COMPARATOR
Intervention: Clinic school with strong AIDS education program
Number of subjects: 0
Study 2029947 — intervention group
Group type: COMPARATOR
Intervention: Clinic school prioritizing pregnancy prevention with contraceptive vouchers
Number of subjects: 0
Study 2029947 — intervention group
Group type: COMPARATOR
Intervention: Clinic school focusing on high-risk youth and dispensing birth control pills
Number of subjects: 0
Study 2029947 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall impact of clinics on pregnancy rates
Number of subjects: 0
Study 30945822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 2000
Study 30945822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 28542285 — intervention group
Group type: EXPERIMENTAL
Intervention: iLook Out for Child Abuse educational intervention
Number of subjects: 762
Study 28542285 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 762
Study 26121561 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 4158
Study 26121561 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 4158
Study 26121561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4158
Study 23874572 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 75
Study 23874572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 21285532 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly-licensed vaccine (Fluarix™)
Number of subjects: 1845
Study 21285532 — intervention group
Group type: COMPARATOR
Intervention: Established vaccine
Number of subjects: 1845
Study 19583486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine in patients with normal thyroid function (n=15)
Number of subjects: 67
Study 19583486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline in patients with normal thyroid function (n=14)
Number of subjects: 67
Study 19583486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine in patients with hypothyroidism (n=13)
Number of subjects: 67
Study 19583486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline in patients with hypothyroidism (n=15)
Number of subjects: 67
Study 19583486 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10) with hypothyroidism on levothyroxine therapy without depression
Number of subjects: 67
Study 17377119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 56
Study 17377119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 56
Study 17377119 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 56
Study 15264733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 50 microg/kg
Number of subjects: 210
Study 15264733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 100 microg/kg
Number of subjects: 210
Study 15264733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 200 microg/kg
Number of subjects: 210
Study 15264733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 250 microg/kg
Number of subjects: 210
Study 15264733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 210
Study 15264733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (all dosages)
Number of subjects: 210
Study 11554953 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U botulinum toxin injected into frontal and temporal muscles
Number of subjects: 0
Study 11554953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9754972 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Impact (HIP) aerobic dance session
Number of subjects: 10
Study 9754972 — intervention group
Group type: COMPARATOR
Intervention: Low-Impact (LIP) aerobic dance session
Number of subjects: 10
Study 9754972 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between HIP and LIP sessions
Number of subjects: 10
Study 8140666 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 123
Study 8140666 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Control)
Number of subjects: 123
Study 3169222 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 24
Study 3169222 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 24
Study 3169222 — intervention group
Group type: COMPARATOR
Intervention: Ambient air (placebo with noisy nebulizer)
Number of subjects: 24
Study 3169222 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (air without nebulizer)
Number of subjects: 24
Study 31162898 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral supine mini-percutaneous nephrolithotomy (n=37)
Number of subjects: 79
Study 31162898 — intervention group
Group type: COMPARATOR
Intervention: Staged mini-percutaneous nephrolithotomy (n=42)
Number of subjects: 79
Study 31162898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study 31162898 — intervention group
Group type: EXPERIMENTAL
Intervention: Main group
Number of subjects: 79
Study 31162898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 28657803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) - 50 min cycling at 75% VO2peak
Number of subjects: 12
Study 28657803 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength exercise (SE) - 10 × 8 leg extensions at 75% 1RM
Number of subjects: 12
Study 28657803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (CE) - 50% SE + 50% AE
Number of subjects: 12
Study 28657803 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control (CON) - 50 min seated rest
Number of subjects: 12
Study 25709702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage applied to LI4 during four contractions
Number of subjects: 150
Study 25709702 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group with pressure applied to LI4 using silicone balloons
Number of subjects: 150
Study 25709702 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 150
Study 23453404 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg single dose)
Number of subjects: 34
Study 23453404 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (adjusted doses based on Child‐Pugh classification)
Number of subjects: 34
Study 23453404 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds for dose adjustment
Number of subjects: 34
Study 23453404 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events assessment
Number of subjects: 34
Study 20934702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (42 nurses)
Number of subjects: 90
Study 20934702 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (38 nurses)
Number of subjects: 90
Study 20120790 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation
Number of subjects: 843
Study 20120790 — intervention group
Group type: COMPARATOR
Intervention: Iron‐folic acid supplementation
Number of subjects: 843
Study 17121506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention pharmacists received video-conference training on the management of depression and provided medication with extra advice and support.
Number of subjects: 106
Study 17121506 — intervention group
Group type: COMPARATOR
Intervention: Control pharmacists provided usual care.
Number of subjects: 106
Study 15249281 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg nightly for 4 weeks
Number of subjects: 26
Study 15249281 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly for 4 weeks
Number of subjects: 26
Study 11479064 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection (ED) system implemented in Rogaland, Norway
Number of subjects: 0
Study 11479064 — intervention group
Group type: COMPARATOR
Intervention: Usual detection and referral systems in Ullevål, Norway, and Roskilde, Denmark
Number of subjects: 0
Study 9126668 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ascorbic acid concentration in smokers
Number of subjects: 51
Study 9126668 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum urate concentration in non-smokers
Number of subjects: 51
Study 9126668 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma TRAP
Number of subjects: 51
Study 9126668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid peroxidation resistance in serum or plasma
Number of subjects: 51
Study 8482063 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID + misoprostol 200 mcg bid
Number of subjects: 95
Study 8482063 — intervention group
Group type: COMPARATOR
Intervention: NSAID alone
Number of subjects: 95
Study 3688315 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (200 mg) twice/day for 5 days
Number of subjects: 53
Study 3688315 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of trimethoprim (600 mg)
Number of subjects: 53
Study 3688315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 30757908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led lipid-lowering intervention
Number of subjects: 0
Study 30757908 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 28715853 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 28715853 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0
Study 25682550 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 4 mg
Number of subjects: 0
Study 25682550 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1 mg
Number of subjects: 0
Study 25682550 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 2 mg
Number of subjects: 0
Study 25682550 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (1.23-1.89 kg weight gain)
Number of subjects: 0
Study 25682550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25682550 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (4.2%-6.5%)
Number of subjects: 0
Study 23565580 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine
Number of subjects: 13
Study 23565580 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 13
Study 21967319 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of gel mat
Number of subjects: 100
Study 21967319 — intervention group
Group type: COMPARATOR
Intervention: No gel mat
Number of subjects: 100
Study 19922098 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg once daily
Number of subjects: 500
Study 17097752 — intervention group
Group type: EXPERIMENTAL
Intervention: H-FABP using the CardioDetect assay
Number of subjects: 108
Study 15317401 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fondaparinux 2.5 mg once/day
Number of subjects: 0
Study 15317401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of fondaparinux
Number of subjects: 0
Study 15515537 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuanghuanglian
Number of subjects: 95
Study 15515537 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 95
Study 9650328 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (200 mg)
Number of subjects: 22
Study 9650328 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantago psyllium mucilage (15 g)
Number of subjects: 22
Study 9650328 — intervention group
Group type: COMPARATOR
Intervention: Control (only bread)
Number of subjects: 22
Study 7661413 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulization with albuterol (15 mg/hour)
Number of subjects: 0
Study 7661413 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with spacer device delivering albuterol
Number of subjects: 0
Study 2797066 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (4 ml; 10 mg per milliliter)
Number of subjects: 11
Study 2797066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 740584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical 'high-dose' oestrogens
Number of subjects: 62
Study 740584 — intervention group
Group type: COMPARATOR
Intervention: Cyclical 'low-dose' oestrogens
Number of subjects: 62
Study 740584 — intervention group
Group type: COMPARATOR
Intervention: Cyclical-sequential oestrogen/progestogen regimens
Number of subjects: 62
Study 740584 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hormonal therapy
Number of subjects: 62